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ORIGINAL ARTICLE
Appropriate selection for omalizumab treatment in patients with severe
asthma?
Leo Nygaarda, Daniel Pilsgaard Henriksenb,c, Hanne Madsena and Jesper Rømhild Davidsen a,b,d
aDepartment of Respiratory Medicine, Odense University Hospital, Odense C, Denmark; bResearch Unit of Respiratory Medicine, Clinical
Institute, University of Southern Denmark, Odense C, Denmark; cDepartment of Clinical Biochemistry and Pharmacology, Odense University
Hospital, Odense C, Denmark; dSouth Danish Center of Interstitial Lung Diseases (SCILS), Odense University Hospital, Odense C, Denmark
ABSTRACT
Background: Omalizumab improves asthma control in patients with uncontrolled severe allergic
asthma; however, appropriate patient selection is crucial. Information in this field is sparse.
Objective: We aimed to estimate whether potential omalizumab candidates were appropriately
selected according to guidelines, and the clinical effect of omalizumab treatment over time.
Design: We performed a retrospective observational study on adult patients with asthma treated
with omalizumab during 2006–2015 at the Department of Respiratory Medicine at Odense
University Hospital (OUH), Denmark. Data were obtained from the Electronic Patient Journal of
OUH and Odense Pharmaco-Epidemiological Database. Guideline criteria for omalizumab treat-
ment were used to evaluate the appropriateness of omalizumab candidate selection, and the
Asthma Control Test (ACT) to assess the clinical effects of omalizumab at weeks 16 and 52 from
treatment initiation.
Results: During the observation period, 24 patients received omalizumab, but only 10 patients
(42%) fulfilled criteria recommended by international guidelines. The main reasons for not ful-
filling the criteria were inadequately reduced lung function, insufficient number of exacerbations,
and asthma standard therapy below Global Initiative for Asthma (GINA) step 4–5. Seventeen and
11 patients completed treatment at weeks 16 and 52, with a statistically significant increase in
ACT score of 5.1 points [95% confidence interval (CI) 3.1–7.2, p = 0.0001] and 7.7 points (95% CI
4.3–11.1, p = 0.0005), respectively.
Conclusion: Only 42% of the omalizumab-treated patients were appropriately selected according
to current guidelines. Still, as omalizumab showed significant improvement in asthma control
over time, it is important to keep this drug in mind as an add-on to asthma therapy in well-
selected patients.
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Introduction
The main goal of asthma management is to achieve and
maintain symptom control and normal activity levels,
and to minimise the future risk of exacerbations [1,2].
Inadequately controlled asthma affects both patients
and society in terms of days lost from work and school,
reduced quality of life (QoL), and avoidable healthcare
visits and hospitalisations [3]. Since asthma affects
around 300 million people worldwide, this is a major
public health problem and managing patients with
severe asthma, in particular, can be a challenge [4].
Despite treatment with inhaled corticosteroids (ICS)
and long-acting β2-agonists (LABA), severe asthma is
often uncontrolled and accounts for up to 80% of the
total costs of asthma, even though severe asthma repre-
sents only 5–10% of the total asthma population [4,5].
Omalizumab is a monoclonal antibody indicated as
add-on therapy for patients with severe persistent
asthma. Approximately 50% of patients with uncon-
trolled severe asthma have an immunoglobulin E (IgE)-
mediated phenotype [4,6]. IgE plays an important role
in allergic asthma and particularly in the acute
response to antigens and in the proliferation of airway
inflammation [7]. Omalizumab inhibits binding of free
IgE to high-affinity receptors on pro-inflammatory
cells, which clinically correlates with a reduction in
asthma symptoms and exacerbations [8,9].
Clinical trials and observational studies have shown
omalizumab to significantly reduce exacerbation rates
and frequency of hospitalisations, together with
improving both asthma QoL scores and symptom con-
trol [4,10–12]. Since uncontrolled severe asthma is a
major healthcare problem, it is crucial that potential
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candidates for omalizumab treatment are selected
appropriately, according to current guidelines.
Omalizumab is a rather expensive treatment, with a
cost per defined daily dose (DDD) of around €50,
necessitating good compliance with regular outpatient
clinic attendance. Only scant evidence exists on the
appropriateness of selection, use, and clinical effective-
ness of omalizumab. Hence, the objectives of this study
were to assess, first, whether asthma patients treated
with omalizumab were selected appropriately accord-
ing to current guidelines; and secondly, the clinical
effect of omalizumab treatment assessed according to
changes in asthma symptoms, lung function, asthma
control medication, and asthma exacerbations over
time.
Methods
Design
We performed a retrospective, observational study in
adult patients with severe allergic asthma treated with
omalizumab in the Region of Southern Denmark during
an observational period from 1October 2006 to 31March
2015. Data were analysed using longitudinal and indivi-
dual repetitive cross-sections according to scheduled fol-
low-ups.
Setting
In the Region of Southern Denmark, examination
and treatment of severe asthma, including specia-
lised treatment with omalizumab, are managed at
the Department of Respiratory Medicine at Odense
University Hospital (OUH). This patient category is
primarily assessed in the outpatient clinic, which
acts as a secondary and tertiary specialist unit ser-
ving a population of nearly one million people aged
≥ 15 years (1 January 2015) [13]. Before receiving
omalizumab, all patients go through a preliminary
examination about 1 or 2 weeks before the index
date, defined as the day of omalizumab initiation, to
secure appropriate selection and to determine the
correct dose based on weight and IgE level.
Omalizumab is indicated only for patients fulfilling
the following criteria: age ≥ 6 years; severe persis-
tent asthma; documented positive skin test or in
vitro reactivity to a perennial aeroallergens; frequent
daytime symptoms or night-time awakenings;
asthma exacerbations requiring systemic glucocorti-
coids despite daily high-dose ICS [or leukotriene
receptor antagonist (LTRA)] and LABA; weight of
20–150 kg; total IgE at 30–1500 IU/mL; and for
patients aged ≥ 12 years, forced expiratory volume
in 1 sec (FEV1) < 80% [1,14–16]. In accordance
with the omalizumab European Union (EU) label
and guidelines from the Danish Society of
Respiratory Medicine, the treatment effect was eval-
uated after 16 weeks, and if the treatment was
continued further evaluation was performed at
annual visits [14,16,17].
Data sources
The data for this study were obtained from two clinical
databases: the Electronic Patient Journal (EPJ) of OUH
and the Odense Pharmaco-Epidemiological Database
(OPED).
EPJ
EPJ contains journal data on patients from all admis-
sions and outpatient clinic visits. The data include
medication status, pulmonary function tests (PFTs),
Asthma Control Test (ACT) score, and blood sample
results. Furthermore, EPJ contains information on hos-
pital electronic medical record systems from all
regions, providing an overview of a patient’s medical
record in relation to a hospital visit.
Since 2006, the Department of Respiratory Medicine at
OUH has systematically registered all patients treated with
omalizumab, comprising a total cohort of 32 patients.
OPED
Information on reimbursed drug dispensing in the
County of Funen has been recorded in the OPED
since 1990, and from 1 January 2007 for the entire
Region of Southern Denmark (population 1.2 million)
[13,18]. Each prescription record includes a person
identifier, the date of dispensing, and the brand, active
substance, quantity, and form of the drug. The sub-
stances and quantities are registered according to the
Anatomical Therapeutic Chemical Classification
System (ATC) of the World Health Organization and
DDD methodology [19]. The indication for treatment
and the dosing instruction are not recorded. Drugs not
reimbursed and therefore not recorded in the database
are over-the-counter drugs and some non-reimbursed
prescription drugs, mainly oral contraceptives, hypno-
tics, sedatives, some antibiotics and intranasal drugs for
rhinitis, but also drugs registered only for hospital use,
e.g. omalizumab [20].
Study population
Among the cohort of omalizumab-treated asthma
patients, only those from whom we received
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informed written consent were included. All data
were anonymised. Owing to treatment evaluation
taking place after 16 weeks, only patients fulfilling
16 weeks of treatment were included for objective 2.
For each included patient, EPJ data related to
omalizumab treatment (e.g. PFTs, smoking history,
ACT score, and IgE levels) were retrieved and indir-
ectly used for manually validating the asthma diag-
nosis and the appropriateness of omalizumab
treatment. The total number of admissions 1 year
before omalizumab initiation and documentation of
allergy tests were sought and validated through old
records, e.g. former admission journals and discharge
summaries.
OPED were used to retrieve data on all redeemed
individual medication from 1990 to 31 March 2015.
Prescriptions redeemed before omalizumab treatment
were used to classify comorbidities (comorbidities
according to ATC codes, Appendix I). The date of
omalizumab initiation was defined as the index date
for the individual patient. As a surrogate marker of
compliance with asthma controller medication, i.e.
ICS (ATC R03BA), LABA (ATC R03AC12
R03AC13), ICS/LABA (ATC R03AK06, R03AK07,
R03AK08, R03AK09, R03AK10, and R03AK11), or
LTRA (ATC R03DC), we used a definition of having
redeemed prescriptions of either ICS and LABA, or
LTRA and LABA 6 months before the individual
index date.
Outcome variables
Objective 1
The primary outcome was to determine the proportion
of appropriate selected patients initiated with omalizu-
mab on the basis of guideline recommendations [16].
We defined severe persistent asthma according to the
European Respiratory Society/American Thoracic
Society definition of severe asthma, and the criteria
regarding frequent daily or nocturnal symptoms were
fulfilled when patients had an ACT score below 20
points, equivalent to uncontrolled asthma [5]. The
number of prescriptions for systemic glucocorticoids
(ATC H02AB) was used as a surrogate marker of
asthma exacerbations before and during treatment
with omalizumab. Primary compliance to medication
(i.e. at least one redeemed prescription for asthma
control medication) was measured using the OPED.
Objective 2
Patients completing 16 weeks of omalizumab treatment
were included (Figure 1). The primary outcome was
asthma control measured by the use of ACT, a simple
quantitative tool for assessing asthma control consist-
ing of a validated five-item questionnaire. Each item is
scored on a five-point Likert scale from 1 to 5
(1 = worst; 5 = best), and total scores of 5–19 and
20–25 points reflect uncontrolled and well-controlled
asthma, respectively. The minimal clinically important
Figure 1. Flowchart for enrolment of patients in the study. The numbers of patients completing 2 and 3 years of therapy were
considered too small for analysis. *Patients used for objective 1; **patients used for objective 2. 1Cause of missing contact: death (1),
missing contact information (2); 2side effects registered: general physical discomfort (1), arthralgia (1), headache, fatigue and
dyspnoea (1).
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difference (MCID) is 3 ACT points [21]. Asthma con-
trol was measured by the ACT at the preliminary
examination and at scheduled follow-ups. The latter
also applied to secondary outcomes such as changes
in PFTs, asthma medication status, and number of
exacerbations.
On the basis of redeemed prescriptions, comorbid-
ities were categorised using the same categorisation as
validated by Kuo et al. [22]; however, corticosteroids for
systemic use (ATC H02A) were removed from the rheu-
matic category owing to an essential overlap with treat-
ment of asthma exacerbations.
Data analysis
Using the unique civil registration number (CRN)
assigned to every Danish citizen, relevant information
was retrieved and linked from the above-mentioned
data sources. Outcomes according to the objectives
were analysed for each patient according to cross-sec-
tional measurements at the index date, at 16 weeks
from treatment initiation, and at 52 weeks of follow-up.
We used a paired t-test to analyse whether the
effects on ACT score and PFT measurements were
statistically significant. A Q-Q plot for normal distribu-
tion was generated before the use of the paired t-test. If
a normal distribution was not present, we used the
Wilcoxon matched-pairs signed-rank test and
Wilcoxon rank-sum test for unmatched data.
Missing values related to objective 1 were registered
as ‘criterion not fulfilled’, whereas missing values in
relation to objective 2 were treated with pairwise dele-
tion. Statistical analyses were performed using Stata
version 13.0 (StataCorp, College Station, TX, USA). A
p value < 0.05 was considered statistically significant.
According to Danish law, no ethical approval is
needed for register-based studies. The Danish Data
Protection Agency (J no. 2008-58-0035) approved the
study. All patients gave written informed consent.
Results
In total, 32 patients were treated with omalizumab
from 1 October 2006 to 31 March 2015. The flowchart
for enrolment is presented in Figure 1 and baseline
data are presented in Table 1.
Objective 1
In total, 24 omalizumab-treated patients (54% women)
who had undergone a preliminary examination were
included for objective 1 (Table 2). Five of these patients
(21%) had no redeemed prescriptions for asthma con-
trol medication and were therefore categorised as non-
compliant with asthma control medication, and in nine
patients either data on previous treatment were una-
vailable (n = 2) or criteria for FEV1, exacerbations, or
ACT score were not met. According to guideline
recommendations, 10 patients (42%) of the study
population fulfilled all criteria for omalizumab treat-
ment. The number of patients fulfilling the criteria
Table 1. Baseline characteristics.
Characteristics
Study population
(N = 24)
Age (years) 43 ± 12
Women 13 (54)
IgE level (IU/mL) 235 ± 190
Body mass index (kg/m2) 30.8 ± 6.4
Omalizumab dose (mg/4 weeks) 422 ± 225
Correct omalizumab dose 18 (75)
ACT score a 12.4 ± 4.5
FEV1% predicted (L) 2.30 (69) ± 0.83 (21)
FVC% predicted (L) 3.22 (82) ± 0.90 (17)
FEV1/FVC 71.0 ± 15.1
PEF (L/min) 365 ± 113
Admissions (in year preceding index date), mean 0.71
Exacerbations (in year preceding index date),
meanb
2.64
Perennial aeroallergen 23 (96)
GINA step
4 19 (79)
5 5 (21)
Tobacco
Never-smoker 12 (50)
Ex-smoker 12 (50)
Comorbiditiesb
Coronary and peripheral vascular diseases
(antiplatelets and anticoagulants)
2 (9)
Hypertension 4 (17)
Hyperlipidaemia 1 (4)
Ischaemic heart disease 1 (4)
Congestive heart disease (/hypertension) 3 (13)
Diabetes 1 (4)
Acid peptic disease 11 (48)
Thyroid disorders 1 (4)
Chronic IBD 1 (4)
Pain (inflammation) 16 (70)
Pain 8 (35)
Depression 5 (22)
Psychotic illness 1 (4)
Ischaemic heart disease (/hypertension) 3 (13)
Comorbidity, frequencyb
0–2 12 (52)
3–4 7 (30)
5–6 2 (9)
≥7 2 (9)
Continuous data are shown as mean ± SD and categorical data as number
(%).
a Two patients had no registered Asthma Control Test (ACT) score at the
index date.
b One patient lacked information about redeemed prescriptions, as the
Odense Pharmaco-Epidemiological Database (OPED) the Region of
Southern Denmark outside Funen until 2007.
IgE, immunoglobulin E; FEV1, forced expiratory volume in 1 sec; FVC, forced
vital capacity; PEF, peak expiratory flow; GINA, Global Initiative for Asthma;
IBD, inflammatory bowel disease.
4 L. NYGAARD ET AL.
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remained unchanged when adding primary compliance
with control medication (i.e. ICS, ICS/LABA, and
LTRA/LABA) [16].
Objective 2
During the observation period, 18 and 12 patients
completed 16 and 52 weeks of treatment, respectively.
However, one patient was excluded owing to a missing
ACT score at the index date. A statistically significant
increase in mean ACT score by 5.1 points [95% con-
fidence interval (CI) 3.1–7.2, p = 0.0001] was found
when comparing ACT scores from the index date and
at 16 weeks’ follow-up, and 11 patients (65%) had a
clinically significant increase of ≥ 3 points in total ACT
score. For patients completing 52 weeks of treatment,
mean ACT scores increased by 7.7 points (95% CI 4.3–
11.1, p = 0.0005) and nine (82%) patients had a clini-
cally significant increase in ACT score compared with
the index date. Figure 2 illustrates a significant
improvement in the proportion of controlled patients,
with five (p = 0.03) and seven (p = 0.01) further
patients having ACT scores of ≥ 20 after 16 and
52 weeks of omalizumab treatment, respectively.
Women had a 4.56 point (95% CI 0.84–8.28,
p = 0.02) higher increase than men in mean ACT
score from the index date to the 16 week follow-up,
and the same tendency was present after 52 weeks, with
a 6.39 point mean ACT score increase (p > 0.05) for
women. The ACT mean scores increased in the two
follow-ups in both genders, but only women had a
statistically significant increase.
The mean FEV1% predicted for patients completing
52 weeks of omalizumab treatment showed a slight
change from the index date to 16 and 52 weeks of
follow-up, corresponding to 11 percentage points
(95% CI 1–20, p = 0.03) and 10 percentage points
(95% CI 0–21, p = 0.05), respectively. The matching
changes in mean FEV1 were 0.31 L and 0.29 L, respec-
tively. The remaining PFT measurements showed no
significant changes, and are illustrated in Table 3
together with mean biannual exacerbation rates for
the patients completing 52 weeks of treatment.
The mean number of exacerbations decreased
throughout the 52 weeks. However, one patient was
responsible for the majority of the total number of
exacerbations, corresponding to seven out of 11
(64%) and four out of seven (57%) exacerbations,
respectively, after 16 and 52 weeks of omalizumab
treatment. Furthermore, we found that the frequency
of annual asthma exacerbations reduced by 28% or an
average of 0.64 (p > 0.05) exacerbations compared to
the year before the index date (data not shown).
No significant difference was found in asthma con-
trol between appropriately selected versus non-appro-
priately selected patients when stratifying for variables
such as correct omalizumab dose, obesity [body mass
index (BMI) > 30 kg/m2], smoking status, and compli-
ance with asthma control medication.
Discussion
The main finding of this study was that only 42% of the
patients with severe asthma treated with omalizumab
had been appropriately selected according to current
guidelines [1,14–16]. Despite this, omalizumab had a
significant effect on asthma control, with an increase in
mean ACT score of 5.1 and 7.7 at 16 and 52 weeks’
follow-up, respectively, and with the highest mean
ACT scores in women and no significant increase in
men. Although not statistically significant, a trend
towards a reduction in numbers of exacerbations was
observed after 52 weeks of omalizumab treatment com-
pared to before initiation of omalizumab treatment. In
addition, obesity seemed to be a general trait among all
omalizumab-treated patients.
According to objective 1, previous studies have not
paid much attention to the appropriateness of selecting
patients for omalizumab treatment in clinical settings,
which is why there is no direct frame of reference.
Changes in the selection criteria during the observation
period could, however, have had a negative influence
on the overall proportion of well-selected patients, as
the criteria used in this study are based on current
guideline recommendations [1,14–16]. Thus,
Table 2. Fulfilled omalizumab selection criteria.
Criteria Fulfilled, N (%)
Age ≥ 6 years 24 (100)
Severe asthma 24 (100)
Achieved compliance with asthma control medication 19 (79)a
ACT < 20 20 (83)b
FEV1 < 80% (if ≥ 12 years) 17 (71)
Perennial aeroallergen 23 (96)
≥ 1 exacerbation 19 (79)c
Weight [20;150] kg 24 (100)
Total IgE [30;1500] IU/ml 24 (100)
All criteria fulfilled 10 (42)
a Two patients lacked information about redeemed prescriptions as the
Odense Pharmaco-Epidemiological Database (OPED) did not cover the
Region of Southern Denmark outside Funen before 2007.
b Two patients had no Asthma Control Test (ACT) score registered at the
index date. The missing values were registered as ACT > 20.
c One patient lacked information about redeemed prescriptions as OPED
did not cover the Region of Southern Denmark outside Funen before
2007.
FEV1, forced expiratory volume in 1 sec; IgE, immunoglobulin E.
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comparing the number of treated patients and the
possible number of patients eligible for omalizumab
treatment seems somewhat contradictory. The current
selection seems inadequate owing to a low number of
omalizumab-treated patients fulfilling the selection cri-
teria, and more patients are expected to be treated with
omalizumab according to asthma prevalence. In
Denmark, the prevalence of asthma in adults is around
7%, of whom 8% can be classified as having severe
asthma [23,24]. If at least 50% have allergic asthma,
2,800 adults are likely to have severe allergic asthma in
the Region of Southern Denmark. This number may be
a rough estimate, but the number of treated patients in
our study and the expected number of patients treated
with omalizumab differ. This difference is probably due
to multiple factors, including attitudes towards treat-
ment, symptom neglect among patients, socio-eco-
nomic factors such as disposable income, the treating
physician’s knowledge of severe asthma and available
insight into the guidelines, deselection of treatment,
and bottlenecks in referral to tertiary asthma centres
[25,26]. A major study by Buhl et al. supports this
explanation [27].
The results of objective 2 are consistent with find-
ings from previous studies documenting that treatment
with omalizumab in patients with severe persistent
Figure 2. Changes in Asthma Control Test (ACT) score after 16 and 52 weeks of treatment for 17 and 11 patients, respectively. Each
line represents a patient and the dotted line represents the mean ACT score. At the 16 and 52 week follow-up the mean ACT score
was 17.5 and 19.3, respectively.
Table 3. Development in mean pulmonary function test (PFT) measurements and mean exacerbation rates for
patients completing 52 weeks of treatment.
Characteristics Baseline 16 weeks 52 weeks
FEV1% predicted (L)
(n = 12) 2.16 (69) ± 0.67 2.47 (81) ± 0.55 2.45 (81) ± 0.62
FVC% predicted (L)
(n = 12) 3.06 (84) ± 0.75 3.34 (89) ± 0.62 3.27 (89) ± 0.69
PEF (L/min)
(n = 9)b 352 ± 56 403 ± 77 402 ± 70
Exacerbationsa
(n = 11)b 1.27 ± 0.9 1 ± 2.1 0.64 ± 1.2
Data are shown as mean (%) ± SD; n indicates the number of patients included.
a The exacerbation rates are biannual and account for the mean number of exacerbations (1) during the 180 days preceding the
index date, (2) from the index date to 180 days afterwards, and (3) from 180 to 360 days of treatment, respectively.
b Because of no registered peak expiratory flow (PEF) measurements and missing information about redeemed prescriptions from
the Odense Pharmaco-Epidemiological Database (OPED), only nine and 11 patients were included in calculations of PEF and
exacerbation rate, respectively.
FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity.
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asthma increases asthma control and reduces exacer-
bation rates [4]. A large, international, observational
study of omalizumab use in 943 patients found similar
results according to ACT score, with an increase of 6.1
on average after 12 months of treatment, and mean
ACT scores at the index date and after 12 months of
13.0 and 19.1, respectively [12]. However, this study
did not aim to assess the appropriateness of selecting
candidates for omalizumab. Since the MCID is 3, the
increase in ACT score indicates that omalizumab
improved asthma control to a level of clinical signifi-
cance. Because of the small study population, we had
very few patients with admissions due to asthma, so it
was not possible to perform any significant analysis on
the effectiveness of omalizumab in reducing hospitali-
sations due to asthma.
Women had better asthma control than men at both
16 and 52 weeks. The association between gender and
asthma control may be confounded by the higher BMI
among women (BMI: women 33 kg/m2 and men 28 kg/
m2; data not shown), as obesity is a known predictor of
poor asthma control [2014,29]. However, female gen-
der was shown to be associated with worse asthma
control in a Spanish cross-sectional study [29].
It is well documented that obesity and uncontrolled
asthma are positively associated [30,31]. We found a high
mean BMI of nearly 31 kg/m2 in our study population,
corresponding to obesity, and although our data cannot
be used to explore for causality, this could be a potential
explanation for a requirement of omalizumab as add-on
therapy to achieve asthma control among these patients.
However, evidence to support the benefit of omalizumab
on asthma control in obese patients is hard to come by, as
most studies investigating the effectiveness of omalizu-
mab have only registered weight, not BMI, making con-
sistent comparisons difficult [12,32,33].
Strengths and limitations
The main strength of the study was the inclusion of all
omalizumab-treated patients from a tertiary referral
asthma centre covering one million inhabitants aged
≥ 15 years, and not least the manual validation of all
data from EPJ, including the asthma diagnosis, sensitisa-
tion to perennial aeroallergens, omalizumab treatment,
IgE level, BMI, and smoking status. Another strength was
the use of electronic pharmacy records, with a high level
of completeness, to account for patients’ medication use
[34]. As prescription data fromOPEDwere extensive and
records completely covered all dispensed drugs, we
avoided the problem of recall bias compared with self-
reporting, where patients with a chronic disease tend to
overestimate their level of compliance [35]. Furthermore,
assessing prescription records retrospectively added an
additional advantage to our study, since it removed the
Hawthorne effect, often seen when patients under obser-
vation improve in their adherence to medication.
Nonetheless, prescription data account only for primary
and not for secondary compliance with medication (i.e.
the patient actually takes the medicine) [20]. In this way,
valid information on real drug use would have been
preferable, e.g. obtained by directly observed therapy or
measurement of concentrations of a drug or its metabo-
lite in the blood or urine. However, such approaches have
major disadvantages in that they can be rather difficult to
administer, expensive, and invasive for the patient.
We may have underestimated the proportion of appro-
priately selected patients, sincemissing values in objective 1
were treated as though the criterion was not fulfilled. This
leaves a risk of differential misclassification according to
OPED data and ACT score. There is also a risk of under-
estimating exacerbation rates, as patients may have
redeemed a large quantity or already have a supply of
systemic glucocorticoids at home and could thereby be
self-administering when symptoms deteriorate. To obtain
a more accurate estimate of exacerbation rates and com-
pliance with asthma control medication, calculation of
DDDs could have been an option. The chosen criteria in
this retrospective study were based on existing guideline
criteria from the European Medicines Agency (EMA), the
UK National Institute for Health and Care Excellence
(NICE), and the Danish Society of Respiratory Medicine,
with only two minor differences. First, in the mentioned
guidelines anACT score < 20was not an inclusion criterion
for omalizumab treatment [14–16]. In our cohort, this
criterion excluded four patients (20 patients included ver-
sus 24 with informed consent), and if this criterion was
omitted three out of the four excluded patients would have
fulfilled all the other inclusion criteria, leaving the total
number of patients fulfilling all criteria at 13 (54.1%). The
second difference was the exacerbation rate. This study
included patients with one or more annual exacerbations,
whereas NICE and EMA refer to ‘multiple exacerbations’,
meaning more than one [14,15]. If the ‘multiple exacerba-
tion’ criterion was used in our cohort and defined as more
than two annual exacerbations, this would exclude five of
the 19 patients registered with exacerbations, leaving the
total number of patients fulfilling all criteria at five (20.8%).
Therefore, the applied and potentially restrictive ACT cri-
terion in our cohort was very likely to have been be coun-
terbalanced by the applied exacerbation criterion. Hence,
we do not think that patients were excluded from omali-
zumab treatment differently from other asthma centres
using the above-mentioned guideline criteria, and as such
we find that the selected patients reliably represent omali-
zumab candidates outside our region and country.
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Another limitation of our study was the lack of power
owing to the small study population. However, since we
included all patients treated with omalizumab in the
Region of Southern Denmark, the only option to enhance
power would be to conduct a multicentre study. We had
an acceptable inclusion response rate of 75%, but it still
entails a risk of selection bias. As the study was retro-
spective and did not require intervention, responders and
non-responders to omalizumab treatment should have
had equal incentive to provide informed consent.
However, responders might have been more enthusiastic
about participating (responders n = 24 versus non-
responders n = 5) (Figure 1), which could have caused a
risk of healthy volunteer bias, a subtype of selection bias.
Conclusion
This study found that only 42% of the patients with
severe asthma treated with omalizumab were appropri-
ately selected according to current guidelines. Yet,
omalizumab is an important add-on treatment option
for well-selected asthma patients, as demonstrated by a
significant improvement in asthma control. Future stu-
dies should focus on how to improve the selection of
patients for omalizumab treatment and encourage
identification of specific determinants of patients who
are likely to benefit from the treatment, rather than the
use of predetermined baseline characteristics.
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